Who qualifies for the Medicare $50 copay on Wegovy Zepbound and Foundayo

Since July 1, people with Medicare drug coverage who meet set weight and health rules can get three obesity drugs for a flat $50 a month. The Medicare $50 copay runs through a temporary program called the GLP-1 Bridge, which lasts until the end of 2027. A Cincinnati TV report this week found pharmacists still fielding a steady flow of new prescriptions. Here is who qualifies under the official rules, which drugs count, and what the low price leaves out.

What the Bridge pays for and when

The Bridge started on July 1, 2026, and is set to run until December 31, 2027, according to the Centers for Medicare and Medicaid Services. The end date was pushed out because a planned replacement, the BALANCE Model, will not launch in 2027. Three products are covered: Foundayo tablets, Wegovy as an injection or a tablet, and Zepbound in the KwikPen only. Zepbound single dose vials and single dose pens are not included. A patient pays $50 for each one month supply, which is 28 or 30 days depending on the drug. The price applies at the pharmacy counter, and the Part D deductible does not apply first. That is the main draw, because the full price of these medicines has been far above what most retirees can pay, with WCPO citing a Wegovy list price above $1,300.

The program sits outside the normal Part D benefit. CMS says drug plans carry no financial risk for these claims and do not have to opt in for their members to use it. Instead, in 2026 a single central processor run for CMS handles prior authorization, decides each claim and pays the pharmacy. That design explains why a patient's own drug plan may know little about the Bridge, and why the copay does not show up on the plan's usual statements. CMS cites a 1967 law that lets it run payment demonstrations as its legal basis. The Bridge follows last year's White House deal with Lilly and Novo Nordisk, which set a path for these drugs into Medicare at a fixed government price.

The BMI rules and who is left out

Eligibility follows firm rules. A patient must have Medicare drug coverage, be 18 or older, and meet one of three body mass index rules when starting treatment, according to Medicare. The broadest is a BMI of 35 or higher on its own. Below that, a qualifying diagnosis is needed, and the list differs by tier. Some local reports have summed this up as a BMI of 27 to 34 with certain health conditions, but the official rules are more specific, as the table shows. Drug coverage counts whether it comes from a standalone Part D plan, most Medicare Advantage plans with drug benefits, Special Needs Plans, employer or union retiree plans, or the LI NET program.

The Bridge started on July 1, 2026, and is set to run until December 31, 2027, according to the Centers for Medicare and Medicaid Services.

Some groups are excluded outright. People whose Part D plan already covers a GLP-1 drug for them cannot use the Bridge. Neither can people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease, because their own plan may already cover these drugs for those conditions under the normal benefit. For them, the price is whatever their plan charges, which can be more than $50 a month. That creates an odd split. Two people taking the same pen may pay very different amounts depending on their diagnosis, not their weight. Before 2026, the agency had dropped a plan to cover obesity drugs, a reversal we reported when Medicare said it would not cover weight loss drugs this year. The Bridge now offers a narrower and temporary route.

How a prescription gets approved

The steps run through the prescriber and the pharmacy. A provider sends a prescription for one of the covered drugs to the pharmacy. When asked, the provider completes a prior authorization and certifies that the patient is using the drug as part of a diet and exercise lifestyle program. The pharmacy may then ask for the Medicare Number or the last four digits of the Social Security Number, and the patient later receives a letter confirming Bridge coverage. Once approved, the prior authorization holds through December 31, 2027, covering refills and dose changes, unless the patient switches to a different GLP-1 drug. A switch means a new approval. CMS has posted a prior authorization form and separate guidance pages for providers, pharmacies and drug plans.

For pharmacies, the work is real. Staff must route these claims to the central processor rather than to the patient's usual plan, and explain to customers why the price differs from what their plan quotes. A Walmart pharmacist told WCPO that prescriptions began arriving from doctors' offices as soon as the program opened. The same pharmacist said home delivery is available for many prescriptions, though delivery terms vary by chain and by state. Once a claim is processed under the Bridge, the patient pays the Medicare $50 copay rather than the price set by their own plan. Patients with questions can call 1-800-MEDICARE, the number CMS lists for Bridge enquiries.

The fine print on the fifty dollar price

The low price comes with limits that matter for budgets. The Medicare $50 copay does not count toward the Part D deductible or the yearly out of pocket limit, so it does not help a patient reach the cap on other drugs. It does not appear on the Part D Explanation of Benefits or the Medicare Summary Notice. Extra Help, the federal subsidy for people with low incomes, cannot reduce it, and CMS says no low income subsidy is paid under the Bridge. The copay also cannot be spread out through the Medicare Prescription Payment Plan. For a patient who already spends heavily on other medicines, the Bridge saves money on the obesity drug while leaving the rest of the drug bill exactly where it was.

The bigger unknown is what happens after 2027. The Bridge is a temporary program with an end date, and CMS has not said what will follow it for people who start treatment now. A coverage gap could leave patients who started in 2026 facing full prices again, and the decision to continue treatment belongs with their prescriber. People who do not qualify still have options worth checking, including the makers' own self pay price for Wegovy, but those prices are far above $50. The official rules, covered drugs and steps are listed on the Medicare GLP-1 Bridge page, which is the place to check before asking a doctor about eligibility.

Conclusion

The Medicare $50 copay is real and running, but it covers three products, set BMI and diagnosis rules, and only until December 31, 2027. People with type 2 diabetes or existing plan coverage are excluded, and the copay does not count toward the Part D cap. Check the official rules, then ask a prescriber about a prior authorization.